Cargando…

The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

INTRODUCTION: New biosimilars of monoclonal antibodies are anticipated to bring significant cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently been approved in Europe in all indications held by reference rituximab (RTX), including rheumatoid arthritis, non-Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gulácsi, László, Brodszky, Valentin, Baji, Petra, Rencz, Fanni, Péntek, Márta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427122/ https://www.ncbi.nlm.nih.gov/pubmed/28397080 http://dx.doi.org/10.1007/s12325-017-0522-y

Ejemplares similares

Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
por: Gulácsi, László, et al.
Publicado: (2017)

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
por: Brodszky, Valentin, et al.
Publicado: (2014)

Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data
por: Brodszky, Valentin, et al.
Publicado: (2017)

Access to biologicals in Crohn’s disease in ten European countries
por: Péntek, Márta, et al.
Publicado: (2017)

Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies
por: Zrubka, Zsombor, et al.
Publicado: (2019)

Cost-of-illness studies in nine Central and Eastern European countries
por: Brodszky, Valentin, et al.
Publicado: (2019)

Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data
por: Baji, Petra, et al.
Publicado: (2020)

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison
por: Baji, Petra, et al.
Publicado: (2014)

A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases
por: Zrubka, Zsombor, et al.
Publicado: (2019)

Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary
por: Péntek, Márta, et al.
Publicado: (2019)

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis
por: Baji, Petra, et al.
Publicado: (2014)

Acceptable health and ageing: results of a cross-sectional study from Hungary
por: Péntek, Márta, et al.
Publicado: (2020)

Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary
por: Rencz, Fanni, et al.
Publicado: (2019)

Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS
por: Zrubka, Zsombor, et al.
Publicado: (2019)

Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs
por: Péntek, Márta, et al.
Publicado: (2017)

Psychometric properties of the Hungarian version of the eHealth Literacy Scale
por: Zrubka, Zsombor, et al.
Publicado: (2019)

Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study
por: Zrubka, Zsombor, et al.
Publicado: (2020)

Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary
por: Baji, Petra, et al.
Publicado: (2020)

Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary
por: Tamás, Gertrúd, et al.
Publicado: (2014)

Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa
por: Almaaytah, Ammar
Publicado: (2020)

Subjective well-being in patients with pemphigus: a path analysis
por: Mitev, Ariel, et al.
Publicado: (2019)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

Patient and general population values for luminal and perianal fistulising Crohn’s disease health states
por: Rencz, Fanni, et al.
Publicado: (2019)

Is the trend of increasing use of patient-reported outcome measures in medical device studies the sign of shift towards value-based purchasing in Europe?
por: Weszl, Miklós, et al.
Publicado: (2019)

Assessment of health state utilities in dermatology: an experimental time trade-off value set for the dermatology life quality index
por: Ruzsa, Gábor, et al.
Publicado: (2022)

Eliciting preferences for outpatient care experiences in Hungary: A discrete choice experiment with a national representative sample
por: Brito Fernandes, Óscar, et al.
Publicado: (2020)

Comparing the measurement properties of the ICECAP-A and ICECAP-O instruments in ages 50–70: a cross-sectional study on a representative sample of the Hungarian general population
por: Baji, Petra, et al.
Publicado: (2021)

Measurement properties of the ICECAP-A capability well-being instrument among dermatological patients
por: Rencz, Fanni, et al.
Publicado: (2021)

A head-to-head comparison of the EQ-5D-5L and 15D descriptive systems and index values in a general population sample
por: Nikl, Anna, et al.
Publicado: (2023)

The Budget Impact of Biosimilar Infliximab (Remsima(®)) for the Treatment of Autoimmune Diseases in Five European Countries
por: Jha, Ashok, et al.
Publicado: (2015)

Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets
por: Jang, Minyoung, et al.
Publicado: (2020)

Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries
por: El Zorkany, Bassel, et al.
Publicado: (2018)

Hungarian PROMIS-29+2: psychometric properties and population reference values
por: Jenei, Balázs, et al.
Publicado: (2023)

The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys
por: Baji, Petra, et al.
Publicado: (2019)

Unmet medical needs in ambulatory care in Hungary: forgone visits and medications from a representative population survey
por: Lucevic, Armin, et al.
Publicado: (2019)

Patient experiences with outpatient care in Hungary: results of an online population survey
por: Brito Fernandes, Óscar, et al.
Publicado: (2019)

Self-Reported Waiting Times for Outpatient Health Care Services in Hungary: Results of a Cross-Sectional Survey on a National Representative Sample
por: Brito Fernandes, Óscar, et al.
Publicado: (2021)

Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice
por: Herszényi, Krisztina, et al.
Publicado: (2019)

Health utilities and willingness to pay in adult patients with coeliac disease in Hungary
por: Angyal, M. Mercédesz, et al.
Publicado: (2023)

Validation of the Musculoskeletal Health Questionnaire in a general population sample: a cross-sectional online survey in Hungary
por: Hölgyesi, Áron, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hhuh1adrps814jucfq1ef84kus